Intravitreal Bevacizumab for the Treatment of Patients With Low Vision Due to Neovascular Age-related Macular Degeneration
Overview
- Phase
- Phase 3
- Intervention
- Bevacizumab
- Conditions
- Age Related Macular Degeneration
- Sponsor
- IRCCS San Raffaele
- Enrollment
- 20
- Locations
- 1
- Primary Endpoint
- change in best-corrected visual acuity
- Status
- Completed
- Last Updated
- 15 years ago
Overview
Brief Summary
The purpose of this study is to compare the effectiveness of intravitreal bevacizumab injection (IVBI) with respect to simple observation in patients with subfoveal choroidal neovascularisation (CNV) secondary to age-related macular degeneration (AMD) presenting at baseline with best corrected visual acuity (BCVA) less than 20/200.
Detailed Description
There is no clear indication regarding the treatment of patients with subfoveal choroidal neovascularisation (CNV) secondary to age-related macular degeneration (AMD) presenting at baseline with best corrected visual acuity (BCVA) less than 20/200. Treatment of eyes with low visual acuity could lead to a waste of resources, without any functional and social improvements. Aim of the present study is to compare the effectiveness of intravitreal bevacizumab injection (IVBI) with respect to simple observation in
Investigators
Eligibility Criteria
Inclusion Criteria
- •age-related macular degeneration
- •naïve subfoveal choroidal neovascularization
- •best-corrected visual acuity less then 20/200
Exclusion Criteria
- •previous treatments
- •any other condition able to limit the visual improvement
Arms & Interventions
bevacizumab
three-monthly intravitreal bevacizumab, followed by PRN monthly injection on the basis of the detection of any fluid on the optical coherence tomography
Intervention: Bevacizumab
Outcomes
Primary Outcomes
change in best-corrected visual acuity
Time Frame: 6 months
change in best-corrected visual acuity at the end of the follow-up
Secondary Outcomes
- change in central macular thickness(6 months)
- NEI VFQ-25 scores(6 months)